-transparent.png){kind=logo}
Two different commercially available anti-lymphocyte-globulin preparations have been used in 30 recipients of primary cadaveric kidneys. No difference in graft survival was found within three years after transplantation compared to 102 primary cadaceric kidney recipients who only received basic immunosuppression. When only patients completing an intended ALG dosage were considered, the one-year graft survival was 65% compared to 52% in patients not receiving ALG. In this series of ALG treated patients no major benefits were found compared to the basic immunosuppressive regimen used at this transplantation centre.
Related Publications
J Ahlmen, and
B Storm, and
H Brynger, and
L Sandberg, and
L E Gelin
March 1971,
Transplantation proceedings,
J Ahlmen, and
B Storm, and
H Brynger, and
L Sandberg, and
L E Gelin
January 1976,
Postgraduate medical journal,
J Ahlmen, and
B Storm, and
H Brynger, and
L Sandberg, and
L E Gelin
November 1969,
British medical journal,
J Ahlmen, and
B Storm, and
H Brynger, and
L Sandberg, and
L E Gelin
January 1977,
Scandinavian journal of urology and nephrology. Supplementum,
J Ahlmen, and
B Storm, and
H Brynger, and
L Sandberg, and
L E Gelin
December 1992,
American journal of kidney diseases : the official journal of the National Kidney Foundation,
J Ahlmen, and
B Storm, and
H Brynger, and
L Sandberg, and
L E Gelin
April 1985,
Zhonghua yi xue za zhi,
J Ahlmen, and
B Storm, and
H Brynger, and
L Sandberg, and
L E Gelin
January 1968,
Surgical forum,
J Ahlmen, and
B Storm, and
H Brynger, and
L Sandberg, and
L E Gelin
April 1970,
California medicine,
J Ahlmen, and
B Storm, and
H Brynger, and
L Sandberg, and
L E Gelin
October 1987,
Transplantation proceedings,
J Ahlmen, and
B Storm, and
H Brynger, and
L Sandberg, and
L E Gelin
July 1982,
American journal of kidney diseases : the official journal of the National Kidney Foundation,
